clobetasol and Scalp-Dermatoses

Erosive pustular dermatosis (EPD) is a rare chronic inflammatory condition of the scalp and legs that is often difficult to manage. Currently, there are no treatment guidelines.. To systematically assess the existing literature on various treatment modalities and their efficacies when used in the management of EPD.. We searched PubMed, Cochrane Libraries, Scopus, and clicnialtrial.gov databases for articles in the English language with no limited time frame. Emphasis was placed on articles that reported on treatment for EPD.. Of the 168 articles identified by the literature search, 92 met eligibility criteria and were included for qualitative analysis. Efficacious topical treatments included clobetasol, betamethasone, and tacrolimus. Ninety-three and 88% of cases utilizing clobetasol and betamethasone respectively demonstrated improvement or resolution. All 32 cases utilizing tacrolimus reported improvement. Efficacious systemic treatments included oral steroids such as prednisone, methylprednisolone, and dexamethasone. Topical dapsone, photodynamic therapy, systemic steroids, cyclosporine, and oral zinc derivatives were also described with some success.. According to available data, limited solely to case reports and case series, potent topical steroids are an effective treatment option for EPD. Topical tacrolimus may also be considered in cases that require long-term use or maintenance. Other treatment modalities shown to be successful based on high reported efficacy and low rates of recurrence after treatment include topical dapsone, systemic steroids, zinc derivatives, and cyclosporine. Further studies are needed to compare treatment modalities and to establish treatment protocols.

Topics: Administration, Cutaneous; Administration, Oral; Anti-Infective Agents; Betamethasone; Calcineurin Inhibitors; Clobetasol; Dapsone; Dexamethasone; Glucocorticoids; Humans; Leg Dermatoses; Methylprednisolone; Photochemotherapy; Scalp Dermatoses; Tacrolimus

Psoriasis is a chronic, debilitating disease that commonly involves the scalp. Despite a wide range of therapy options, scalp psoriasis remains difficult to treat, highlighting a long-standing unmet need for the safe and effective treatment of scalp psoriasis. Many topical therapies for scalp psoriasis are also difficult or unpleasant to apply, resulting in decreased adherence and efficacy. In brief, the high level of patient dissatisfaction with currently available treatments for psoriasis supports the need for new, effective and well-tolerated treatment options for scalp psoriasis. This article aims to review the efficacy and safety of new formulations and treatment options available to control scalp psoriasis. For example, a new formulation of calcipotriene/betamethasone scalp solution has a rapid onset of action with once daily dosing that improves compliance. The CalePso study examines the safety profile of otherwise established Clobetasol propionate (CP) shampoo 0.05%, and reports that CP shampoo is safe and efficacious in the long-term management of scalp psoriasis. A new foam formulation of coal tar is shown to be cosmetically acceptable and easier to apply.

Topics: Betamethasone; Calcitriol; Clobetasol; Coal Tar; Drug Combinations; Glucocorticoids; Humans; Keratolytic Agents; Psoriasis; Scalp Dermatoses

Topical corticosteroids have been the mainstay of topical anti-inflammatory therapy of psoriasis and are available in different treatment strengths or doses and various formulations or vehicles. Traditional formulations have included ointments, creams, and lotions. More recently, the mid-potency corticosteroid betamethasone valerate (BMV) and the ultra-high-potency corticosteroid clobetasol propionate (CP) have become available in a novel, thermolabile, low-residue foam vehicle for topical application. This review examines recent clinical studies on efficacy and safety of these two new formulations, BMV 0.12% foam (Luxiq; Connetics Corp, Palo Alto, Calif) and CP 0.05% foam (OLUX, Connetics Corp), as treatments for scalp and nonscalp psoriasis. The studies demonstrated that BMV foam and CP foam are safe and effective treatments for psoriasis affecting scalp and nonscalp regions of the body. BMV foam and CP foam were absorbed more rapidly and demonstrated greater total absorption than their respective comparison formulations, namely BMV lotion and CP solution. The foam vehicle also appears to be associated with better compliance and improvements in quality of life. The unique nature of the foam vehicle, together with the positive findings of in vitro studies suggest these new foam formulations may expand the options currently available for combination therapy.

Topics: Administration, Cutaneous; Adult; Betamethasone Valerate; Clobetasol; Cross-Over Studies; Dermatitis, Atopic; Dosage Forms; Double-Blind Method; Female; Forecasting; Humans; Hydrocortisone; Male; Multicenter Studies as Topic; Ointments; Pharmaceutical Vehicles; Psoriasis; Randomized Controlled Trials as Topic; Scalp Dermatoses; Single-Blind Method; Treatment Outcome

Clobetasol propionate foam (clobetasol foam), a new formulation of the superpotent corticosteroid, has anti-inflammatory, antipruritic and vasoconstrictive properties. It was reported that the absorption rate of clobetasol was greater from the foam than from the solution in cadaver skin. In patients with moderate to severe scalp psoriasis, topical application of clobetasol 0.05% foam twice daily for 2 weeks induced significant improvement of all signs and symptoms of the disease compared with placebo. Compared with clobetasol 0.05% solution, clobetasol foam demonstrated greater improvement of scaling after 2 weeks of treatment and after 2 weeks of follow-up. The investigator's global assessment rated 74% of patients in the clobetasol foam group to be clear or almost clear (90 to 100%) of scalp psoriasis compared with 10% of the placebo foam group. Adverse events at the application site of clobetasol 0.05% foam were limited to one case each of dry skin, eczema, and skin hypertrophy. Clobetasol foam 7 g/day for 2 weeks induced reversible suppression of the hypothalamic-pituitary-adrenal axis in 3 out of 13 patients (methodology of assessment not provided).

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Clobetasol; Drug Administration Schedule; Female; Glucocorticoids; Humans; Male; Middle Aged; Scalp Dermatoses

Ingenol mebutate (IngMeb) is approved for treatment of actinic keratoses (AK) and may cause unpredictable local skin responses (LSR).. We sought to investigate whether IngMeb-induced LSR, pain, and pruritus could be alleviated with a topical glucocorticoid and, further, to assess efficacy, cosmetic outcome, and patient satisfaction in patients with severe photodamage.. In this blinded, randomized controlled clinical trial, patients with multiple AK and field cancerization of the face or scalp were treated in 2 areas with IngMeb (0.015%) daily for 3 days. After finalized IngMeb treatment, 1 area was randomized to receive topical clobetasol propionate (0.05%) twice daily for 4 days. Assessments included LSR (0-24; days 1, 4, 8, 15, 57), pain (0-10) and pruritus (0-3; days 1-15), AK clearance (days 15, 57), and cosmetic outcome (0-3; day 57).. Clobetasol propionate application had no influence on LSR (P = .939), pain (P = .500), pruritus (P = .312), or AK cure rate (P = .991). Overall, IngMeb cleared 86% of all AK lesions, exerting a therapeutic effect on all AK severity grades; cure rates were 88%, 70%, and 60% for grade I, II, and III AK, respectively. Skin texture improved significantly in remedied areas (2.0 vs 1.0; P < .001); no hypopigmentation, hyperpigmentation, or scarring were observed.. These results do not provide safety and efficacy beyond 2 months of follow-up.. Application of clobetasol propionate does not alleviate IngMeb-induced LSR after 3 days of IngMeb treatment.

Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Clobetasol; Denmark; Diterpenes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Facial Dermatoses; Female; Follow-Up Studies; Gels; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; Pruritus; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Single-Blind Method; Treatment Outcome

Photodynamic therapy (PDT) is an effective and established treatment for actinic keratoses (AK) and nonmelanoma skin cancer. The main side-effects of PDT are post-treatment erythema and oedema, and pain during illumination. Severe erythema after PDT enhances the down time associated with the treatment.. To evaluate in a randomized intraindividual study whether use of a topical corticosteroid just before and just after PDT would reduce treatment-induced erythema compared with conventional PDT.. Twenty-two patients with multiple AKs in the face and scalp were treated with methyl aminolaevulinate PDT in two symmetrical areas. One area was randomized to superpotent corticosteroid (clobetasol propionate) before and just after PDT. Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated.. Topical corticosteroid significantly reduced PDT-induced erythema (P = 0·012). The complete lesion response rate 3 months after PDT, and PpIX fluorescence prior to illumination did not differ significantly between the two treated areas.. Superpotent corticosteroid before and just after PDT reduced the erythema 24 h after treatment of multiple AKs on the face and scalp. The use of topical corticosteroid did not affect the efficacy of PDT and may be an easy way to make PDT treatment of large visible areas more acceptable.

Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; Clobetasol; Erythema; Facial Dermatoses; Female; Fluoroscopy; Glucocorticoids; Humans; Keratosis, Actinic; Male; Pain; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Scalp Dermatoses; Treatment Outcome

Topical antifungals and corticosteroids are the mainstay of treatment for seborrhoeic dermatitis. The short-contact clobetasol propionate 0·05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis.. To evaluate the efficacy and safety of CP alone and combined with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis.. This randomized and investigator-blinded study consisted of three phases, each lasting 4 weeks. During the treatment phase, subjects were randomized to receive KC twice weekly (K2), CP twice weekly (C2), CP twice weekly alternating with KC twice weekly (C2 + K2) or CP four times weekly alternating with KC twice weekly (C4+K2). All subjects received KC once weekly during the maintenance phase and were untreated during the follow-up phase.. At the end of the treatment phase, all three CP-containing regimens were significantly more efficacious than K2 in decreasing the overall disease severity (P < 0·05). Both combination regimens were also significantly more efficacious than K2 in decreasing each individual sign of the disease (P < 0·05). While the C2 and C4 + K2 groups experienced slight worsening during the maintenance phase, the efficacy of C2 + K2 was sustained and remained the highest among all groups. All regimens were well tolerated without inducing any skin atrophy. Similarly low incidences of telangiectasia, burning and adverse events were observed among the four groups.. The combination therapy of twice-weekly CP alternating with twice-weekly KC provided significantly greater efficacy than KC alone and a sustained effect in the treatment of moderate to severe scalp seborrhoeic dermatitis.

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Clobetasol; Dermatitis, Seborrheic; Dermatologic Agents; Drug Combinations; Female; Humans; Ketoconazole; Male; Middle Aged; Scalp Dermatoses; Severity of Illness Index

Safety and clinical effectiveness of clobetasol-17 propionate 0.05% shampoo have been shown in patients with scalp psoriasis.. First, to evaluate treatment satisfaction, user convenience safety and effectiveness of clobetasol-17 propionate 0.05% shampoo treatment in daily clinical practice. Second, to identify subgroup variables that may predict treatment success or failure.. A total of 56 patients with scalp psoriasis were treated with short-contact clobetasol-17 propionate 0.05% shampoo once daily for 4 weeks. Data on treatment satisfaction, user convenience, safety and effectiveness were assessed on a 7-point Likert scale using postal questionnaires. Subgroup analyses were performed to identify variables that may predict treatment outcome.. A total of 41 patients returned both questionnaires (73%). Positive treatment satisfaction and user convenience were reported by 66% and 79% of patients respectively. Patient-rated indicators for disease severity improved by 39-46% (P < 0.05%). No major side-effects were reported. Subgroup analyses did not reveal any statistically significant patient variable that may predict treatment outcome. However, a tendency towards improved treatment satisfaction was observed in patients who had received fewer topical antipsoriatic treatments previously (P > 0.05).. Short-contact treatment with clobetasol-17 propionate 0.05% shampoo has high user convenience and patient satisfaction rates. Moreover, the treatment is well-tolerated and efficacious from patients' perspective. Subgroup analyses did not reveal factors predicting treatment outcome, although treatment success tended to be more evident in patients who had received fewer treatments previously.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Cross-Sectional Studies; Drug Administration Schedule; Female; Hair Preparations; Humans; Male; Patient Satisfaction; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Surveys and Questionnaires

We evaluated in this study the efficacy and safety of an alternate regimen using clobetasol propionate 0.05% shampoo (CP shampoo) for long-term control of scalp psoriasis. Patients with moderate scalp psoriasis (Global Severity Score [GSS] of 3 on a 0-5 scale) first received CP shampoo once daily for 4 weeks. Patients with a GSS 2) occurred, patients received the 4-week daily CP shampoo treatment. Patients who had a GSS

Topics: Administration, Cutaneous; Adult; Clobetasol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hair Preparations; Humans; Long-Term Care; Male; Middle Aged; Patient Satisfaction; Probability; Psoriasis; Reference Values; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome; Young Adult

Clobetasol propionate (CP) shampoo 0.05% is an efficacious and safe treatment for scalp psoriasis. The aim of this double-blind, randomized, placebo-controlled study was to determine if CP shampoo is suitable for long-term disease control. Participants with moderate to severe scalp psoriasis (global severity score [GSS] of 3 or 4 on a scale of 0 [clear] to 5 [very severe]) first received once daily CP shampoo treatment for up to 4 weeks. Responders were subsequently randomized to receive the CP shampoo or vehicle twice weekly maintenance regimen for up to 6 months. When relapse occurred (defined as GSS > 2), participants resumed once daily CP shampoo treatment; when symptoms diminished (GSS < or = 2), they readopted the twice weekly maintenance regimen. At all visits significantly more participants treated with CP shampoo did not relapse compared with participants treated with vehicle (P < .001). Only approximately one-third of participants treated with vehicle remained relapse free at 1 month, while this rate was observed approximately 3.5 months later (4.5 months after baseline of maintenance phase) in the CP shampoo group. After 6 months 31.1% (33/106) of participants in the CP shampoo group were still relapse free versus 8.1% (9/111) of participants in the vehicle group. There was no greater incidence of skin atrophy, telangiectasia, or hypothalamic-pituitary-adrenal (HPA) axis suppression in the CP shampoo group compared with the vehicle group. Clobetasol propionate shampoo is efficacious and safe for acute management and long-term maintenance of moderate to severe scalp psoriasis.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clobetasol; Double-Blind Method; Female; Glucocorticoids; Hair Preparations; Humans; Male; Middle Aged; Psoriasis; Recurrence; Scalp Dermatoses; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult

Scalp psoriasis has a considerable impact on the quality of life (QOL) of patients, and most patients are dissatisfied with available treatments. Clobetasol propionate shampoo 0.05% has been shown to be effective and safe for moderate to severe scalp psoriasis. We evaluated the effect of clobetasol propionate shampoo on QOL and the degree of participant satisfaction with the product. Participants received once-daily treatment for up to 4 weeks. Their QOL and degree of satisfaction were evaluated by questionnaires. The mean (standard deviation) Dermatology Life Quality Index (DLQI) score decreased significantly from 7.0 (4.9) at baseline to 3.2 (3.2) at week 4 (P<.001). Participants who considered the disease as having a small effect or no effect on their QOL increased from 45.6% at baseline to 81.7% at week 4. Most participants were satisfied with the cosmetic acceptability and the efficacy and safety aspects of the product, considered it better than prior treatments, and would use it again in the future. Therefore, we conclude that treatment with clobetasol propionate shampoo improved the QOL of participants and resulted in high satisfaction.

Topics: Administration, Cutaneous; Clobetasol; Double-Blind Method; Female; Glucocorticoids; History, 17th Century; Humans; Male; Patient Satisfaction; Psoriasis; Quality of Life; Scalp Dermatoses; Surveys and Questionnaires; Treatment Outcome

Seborrheic dermatitis (SD), a common dermatosis associating hyperseborrhea, erythema, itching, and dandruff, has frequent scalp involvement. Malassezia furfur infection seems to play an important role in the condition's etiopathology. Treatment of SD usually consists of corticosteroids or antifungals, such as ketoconazole. The aim of this multicenter, randomized, investigator-blinded, parallel-group pilot study was to evaluate the efficacy and safety of clobetasol propionate shampoo 0.05% after different short-contact application times compared with its vehicle and ketoconazole foaming gel 2% in the treatment of SD of the scalp. For 4 weeks, 55 subjects received one of the following treatments twice weekly: clobetasol propionate shampoo for 2.5, 5, or 10 minutes; clobetasol propionate vehicle for 10 minutes; or ketoconazole foaming gel for 5 minutes before rinsing off. Efficacy criteria included total severity score (TSS) and individual scores of signs such as itching and global improvement. Safety included reporting of burning, overall tolerance, and adverse events. Results showed that an application of clobetasol propionate for 5 and 10 minutes provided a similar mean percentage decrease of TSS, and the mean percentage decrease of TSS for all active groups was significantly superior to that of the vehicle (P < .01). Overall and local safety were good for all treatment groups. The present pilot study demonstrated that a short-contact application of clobetasol propionate shampoo is effective and safe in the treatment of SD of the scalp.

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Clobetasol; Dermatitis, Seborrheic; Female; Hair Preparations; Humans; Male; Pilot Projects; Scalp Dermatoses; Severity of Illness Index; Single-Blind Method; Treatment Outcome

Clobetasol propionate is known to be a very effective treatment for psoriasis; however, its use is limited by potent corticosteroid class related side effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression and atrophogenicity. The aim of this single-center, parallel group, randomized study was to assess the HPA axis suppression potential, atrophogenicity, and ocular tolerability of clobetasol propionate shampoo in 26 patients with scalp psoriasis. Suitable subjects were treated once daily for 4 weeks with clobetasol propionate shampoo, to be rinsed off after 15 minutes or with a leave-on clobetasol propionate gel. The study demonstrated that clobetasol propionate shampoo did not lead to HPA axis suppression or to skin atrophy. Conversely, the gel led to HPA axis suppression and a decrease in skin thickness. Neither formulation had an impact on ocular safety. Despite the short contact application time, the clobetasol propionate shampoo provides similar efficacy results to the gel.

Topics: Administration, Cutaneous; Adult; Atrophy; Clobetasol; Drug Administration Schedule; Female; Hair Preparations; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Ocular Physiological Phenomena; Pituitary-Adrenal System; Psoriasis; Scalp Dermatoses; Skin; Time Factors; Treatment Outcome

The clinical benefit of currently available tar blend shampoos for the treatment of scalp psoriasis is restricted due to their limited efficacy, low cosmetic appeal and potential for carcinogenicity. This 4-week multicentre, randomized, parallel-group, investigator-masked study included 162 subjects and aimed to compare the efficacy, safety and cosmetic acceptability of clobetasol propionate 0.05% shampoo versus a currently marketed tar blend 1% shampoo in subjects with moderate to severe scalp psoriasis. Clobetasol propionate shampoo was superior to tar blend shampoo with respect to all efficacy variables tested (p<0.001): Total and Global Severity Score; erythema; plaque thickening; desquamation; pruritus; total scalp area involved; and the subject's global assessment of clinical improvement. Both treatments were safe and well-tolerated. Furthermore, more subjects indicated that clobetasol propionate shampoo was more cosmetically acceptable than tar blend shampoo. Clobetasol propionate 0.05% shampoo is a good alternative to tar blend shampoo in the treatment of moderate to severe scalp psoriasis.

Topics: Administration, Cutaneous; Clobetasol; Double-Blind Method; Female; Hair Preparations; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Tars; Treatment Outcome

Scalp involvement in psoriatic patients represents a common issue. Treatment of the hairy skin requires adequate pharmaceutical formulations; hence, a new specific shampoo formulation of clobetasol propionate 0.05% was developed by Galderma R&D, Inc.. For this multicenter, randomized, investigator-masked, parallel group study, 151 subjects with moderate to severe scalp psoriasis were randomized to 4 weeks of treatment with clobetasol propionate shampoo or calcipotriol solution.. Clobetasol propionate demonstrated significantly superior efficacy to calcipotriol solution (total severity score: mean difference 0.51, 95% CI 0.05-0.97, p = 0.028; global severity score: mean difference 0.43, 95% CI 0.08-0.78, p = 0.016). Adverse events were more common in the calcipotriol group than in the clobetasol propionate shampoo group. Telangiectasia and skin atrophy did not differ significantly between treatments; however, a burning sensation was significantly more common in the calcipotriol solution group.. Short contact therapy of scalp psoriasis with this new shampoo formulation of clobetasol propionate was significantly more effective and better tolerated than calcipotriol solution for the treatment of scalp psoriasis.

Topics: Administration, Topical; Adult; Calcitriol; Clobetasol; Dermatologic Agents; Female; Hair Preparations; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Solutions; Treatment Outcome

Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.

Topics: Acne Keloid; Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone Valerate; Black or African American; Clobetasol; Female; Humans; Male; Middle Aged; Quality of Life; Scalp Dermatoses; Treatment Outcome

Topics: Administration, Topical; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Clobetasol; Double-Blind Method; Drug Delivery Systems; Female; Glucocorticoids; Humans; Male; Pharmaceutical Vehicles; Psoriasis; Scalp Dermatoses; Solutions; Treatment Outcome

The efficacy and safety of clobetasol propionate 0.05% scalp application was evaluated in 378 patients with moderate to severe scalp psoriasis in a double-blind vehicle-controlled parallel group study. After 2 weeks of twice-daily applications, 81% receiving active drug versus 22% receiving vehicle had clearing of 50% or greater. Complete clearing was seen in 26% with active drug and 1% with vehicle. Local side effects were primarily burning or stinging in 11% and 10% of patients treated on an active or a vehicle regimen, respectively. The morning cortisol levels of 168 patients were checked at baseline and again after 2 weeks of drug therapy. Subnormal morning plasma cortisol values were seen in 5% of the patients receiving active drug and in 5% receiving vehicle; 13% of those taking active drug versus 5% taking vehicle had a 50% or greater decrease in morning cortisol at the 2-week visit compared with baseline values. Clobetasol propionate 0.05% scalp application appears to be a safe and an effective treatment for scalp psoriasis.

Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Clobetasol; Double-Blind Method; Female; Humans; Hydrocortisone; Male; Middle Aged; Psoriasis; Scalp Dermatoses; United States

A double-blind comparison was made between Diprosalic and Dermovate lotions in fifty-one patients with psoriasis of the scalp. Both preparations were highly effective. No significant difference in efficacy between the preparations could be demonstrated after 3 weeks treatment except for antipruritic effect, in this respect Diprosalic being superior to Dermovate. Only three patients (two in the Dermovate group, and one in the Diprosalic group) experienced minor adverse reactions. Plasma cortisol levels were determined in seventeen of the patients and no significant influence on the adrenal function could be shown on the part of either of the preparations.

Topics: Anti-Inflammatory Agents; Betamethasone; Clobetasol; Drug Evaluation; Female; Humans; Hydrocortisone; Male; Psoriasis; Salicylates; Scalp Dermatoses; Suspensions

A double-blind evaluation was carried out in 40 patients with moderate to severe psoriasis of the scalp to assess the effectiveness of a 0.05% alcoholic solution of clobetasol propionate as compared with a 0.05% alcoholic solution of betamethasone-17,21-dipropionate. Patients were treated on a non-selective basis with a twice a day application for 2 weeks. When comparing the effects on the parameters scaling, induration, erythema and itching it was concluded that clobetasol propionate was superior to betamethasone-17,21-dipropionate as an antipsoriatic compound. Clobetasol propionate did not cause any side-effects, while 2 of the patients using betamethasone-17,21-dipropionate developed a forehead folliculitis during the second week of treatment.

Topics: Betamethasone; Clinical Trials as Topic; Clobetasol; Humans; Psoriasis; Scalp Dermatoses

Topics: Administration, Cutaneous; Aged, 80 and over; Aminolevulinic Acid; Clobetasol; Female; Humans; Keratosis, Actinic; Light; Ointments; Photochemotherapy; Photosensitizing Agents; Scalp Dermatoses; Tacrolimus; Treatment Outcome

Topics: Aged, 80 and over; Anti-Inflammatory Agents; Carcinoma, Basal Cell; Clobetasol; Dermatologic Agents; Facial Neoplasms; Humans; Male; Postoperative Complications; Scalp Dermatoses; Skin Neoplasms; Skin Transplantation

Topics: Alopecia; Bone Diseases, Metabolic; Clobetasol; Female; Glucocorticoids; Humans; Hydroxychloroquine; Lichen Planus; Middle Aged; Ossification, Heterotopic; Scalp; Scalp Dermatoses; Skin Diseases, Genetic; Treatment Outcome

Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Scalp; Scalp Dermatoses; Treatment Outcome

Topics: Administration, Cutaneous; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Biopsy; Clobetasol; Diagnosis, Differential; Fusidic Acid; Humans; Male; Scalp Dermatoses; Skin Diseases, Vesiculobullous; Skin Neoplasms

Topics: Aged; Anti-Bacterial Agents; Blister; Clobetasol; Drug Therapy, Combination; Epidermolysis Bullosa; Fusidic Acid; Glucocorticoids; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Periodontal Diseases; Photosensitivity Disorders; Rifampin; Scalp Dermatoses; Treatment Outcome

Lichen planopilaris (LPP) is characterized by lymphocytic infiltrate, fibrosis and potential destruction of the hair follicle. Demographic and clinical studies in LPP are limited, and racial differences have not been thoroughly investigated.. To analyse epidemiological data and clinical profiles of Chilean adults with LPP, and report on the treatments used.. This was a retrospective review of medical records and clinical follow-up of Chilean adults with a clinical and histopathological diagnosis of LPP. Treatment response was categorized clinically as none (with progression of condition), mild or satisfactory.. The study assessed 103 patients with LPP [67 women (mean age 54.1 years) and 36 men (mean age 39.1 years)]. Of the 103 patients, 41 women and 34 men were diagnosed with classic LPP (CLPP) and 26 women and 1 man with frontal fibrosing alopecia (FFA), while Graham-Little-Piccardi-Lassueur syndrome (GLPLS) was identified in 1 man. Men with CLPP had a significantly (P < 0.001) earlier age of onset than women. Scalp dysaesthesia, erythema and peripilar hyperkeratosis were common findings, and 51 (66%) of patients with CLPP had cicatricial patches, most of which were circumscribed in the vertex area. All patients with FFA had band-like scarring in the frontal and temporal hairlines. Morbidities associated with LPP were hypothyroidism, dyslipidaemia, hypertension and depression. For most patients, treatment halted or improved their inflammatory/scarring condition. A sustained combination of at least one topical (clobetasol, minoxidil and salicylic acid) and one systemic (cetirizine, hydroxychloroquine, finasteride, methotrexate and isotretinoin) medication was necessary in all of our patients with LPP.. This investigation is one of the first to describe the demographic, clinical and therapeutic features of LPP in a Latin American population. Similar profiles to previous reports may encourage research in larger multicentre international studies.

Topics: Administration, Topical; Adult; Age of Onset; Alopecia; Cetirizine; Chile; Clobetasol; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Lichen Planus; Male; Middle Aged; Retrospective Studies; Scalp Dermatoses; Sex Distribution; Sex Factors

Topics: Child; Clobetasol; Female; Glucocorticoids; Humans; Keratolytic Agents; Pityriasis; Salicylic Acid; Scalp Dermatoses

Topics: Anti-Inflammatory Agents; Clobetasol; Dermatitis, Allergic Contact; Female; Hair Preparations; Humans; Middle Aged; Plant Oils; Scalp Dermatoses

Topics: Clobetasol; Facial Dermatoses; Female; Glucocorticoids; Humans; Keratosis, Actinic; Male; Scalp Dermatoses

Topics: Alopecia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clobetasol; Diagnosis, Differential; Doxycycline; Folliculitis; Humans; Male; Scalp Dermatoses; Treatment Outcome; Young Adult

Erosive pustular dermatosis (EPD) is a rarely reported condition that primarily involves the actinically damaged scalp of elderly women. Although the condition is well recognized in the United Kingdom and Europe, no US cases have heretofore been reported.. We sought to document the presence, and determine the clinical characteristics, of EPD in the US population.. Patients were recruited from the dermatology clinic at a university in California and from the private practices of dermatologists in the Northern California region.. Eleven patients with EPD were identified. Eight were women and 3 were men. The scalp was involved in 9 patients and the extremities in two patients. The involved skin was actinically damaged in 9 patients. The patients were elderly (66-90 years) but one patient was a 15-year-old boy. All lesions resolved or greatly improved with the application of high-potency steroids or tacrolimus.. Not all patients were examined personally by the authors of this article. The length of follow-up was relatively short.. EPD is a fairly common disease and is the most likely diagnosis in instances where chronic, nonhealing, shallow erosions occur on actinically damaged, or otherwise atrophic, skin. In spite of the name, intact pustules are rarely present. The histology is that of moderate to marked, nonspecific chronic inflammation. EPD responds well to high-potency topical steroids.

Topics: Administration, Topical; Adolescent; Aged; Aged, 80 and over; Atrophy; Calcineurin Inhibitors; Clobetasol; Extremities; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Photosensitivity Disorders; Scalp Dermatoses; Skin Diseases; Skin Diseases, Vesiculobullous; Steroids; Tacrolimus; Treatment Outcome

A 53-year-old woman presented with erosive pustular dermatosis of the scalp 6 weeks after a bifrontal skin flap and right frontal craniotomy had been performed for removal of a suprasellar meningioma. Although some authors consider that acute local trauma is a precipitating factor for this condition, we believe that this is the first reported case following a neurosurgical procedure.

Topics: Clobetasol; Craniotomy; Drug Therapy, Combination; Erythromycin; Female; Humans; Middle Aged; Postoperative Complications; Scalp Dermatoses; Skin Diseases, Vesiculobullous; Surgical Flaps

A case of erosive pustular dermatosis of the scalp is reported. The lesions were eroded with crusting and pustule formation and were localised on the scalp. Investigations for infection, autoimmunity, vascular or tumoral aetiology were negative. Skin biopsy revealed non specific inflammation as usually, but also showed spongiform pustule formations which had not previously been described. Topical corticosteroid therapy dramatically improved the lesions. The pathogenesis of this disease is discussed.

Topics: Administration, Topical; Aged; Clobetasol; Humans; Male; Scalp Dermatoses; Skin Diseases, Vesiculobullous

Topics: Adolescent; Adult; Alopecia; Betamethasone; Child; Child, Preschool; Clobetasol; Dermatitis, Seborrheic; Female; Humans; Male; Middle Aged; Neurodermatitis; Pharmaceutical Vehicles; Pityriasis; Psoriasis; Scalp Dermatoses; Switzerland